Obesity Clinical Trial
Official title:
CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users
NCT number | NCT06467604 |
Other study ID # | 2184712-2 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 12, 2024 |
Est. completion date | December 31, 2025 |
This study aims to assess the impact of GLP-1 receptor agonists, semaglutide and tirzepatide, on food cravings and diet quality in individuals with overweight or obesity. Over 24 weeks, up to 150 adult participants will be monitored using questionnaires and dietary records at 0, 12, and 24 weeks to measure changes in diet quality, disordered eating, food cravings, and hunger. This research, conducted with Seen Medical Group at Knownwell Health Clinic, seeks to fill the gap in literature on the dietary quality effects of GLP-1RAs.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | December 31, 2025 |
Est. primary completion date | September 12, 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Male or female, age 18.0-<70 years 2. Obese (BMI greater than or equal to 30.0 kg/m2) or overweight (BMI greater than or equal to 27.0 kg/m2) with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease and history of at least one self-reported unsuccessful dietary effort to lose body weight will be recruited. 3. On stable regimen of medications that can affect weight or diabetes outcomes for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted) 4. Weight stable (+/- 5%) over previous 3 months 5. Be under the care of a physician who will be responsible for managing participant's treatment regimen 6. Willingness to provide food diary data throughout trial 7. Access to a smartphone/tablet that can download the food logging application 8. Willing and able to provide a valid email address for use in the study 9. Be able to communicate (oral and written) in English 10. Be able to provide informed consent Exclusion Criteria: 1. History of weight loss surgery 2. History of major surgery within three months of enrollment 3. Recent weight fluctuations exceeding 5 kg within a 3-month period preceding screening 4. Use of systemic hormonal therapies (contraceptive medication is allowed) 5. History of Type 1 or type 2 diabetes, HgbA1c = 6.5% (gestational diabetes is allowed) 6. Hemoglobinopathy that interferes with measurement of HbA1c 7. Treatment with any GLP-1 Receptor Agonist medication(s) within 90 days of screening 8. Significant kidney or liver disease, malnutrition, or any condition that, in the investigator's judgment, should exclude participation 9. Documented chronic diseases including thyroid disease, kidney disease, active cancer, previous cardiovascular events, history or presence of chronic pancreatitis, or other gastrointestinal issues 10. Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma 11. Current cancer or cancer treatment, or history of cancer or cancer treatment within the last 3 years, excluding specific cases 12. Diagnosis or strong clinical suspicion of eating disorders 13. Background of significant active or unstable major depressive disorder (MDD) or any other severe psychiatric disorder within the past 2 years 14. Lifetime history of a suicide attempt 15. History of gastroparesis or other gut dysmotility syndrome 16. Prior use of other GLP-1RA or combination GIP/GLP-1RA medications or previous participation in any GLP-1RA trials 17. Pregnant or lactating women, women planning to become pregnant in the next 12 months 18. Multiple patient-reported food allergies/intolerances significantly limiting food intake 19. Smoking, illicit drug use, vaporizer and/or electronic cigarette use 20. Currently consuming >14 alcoholic drinks per week 21. Extreme dietary or exercise patterns 22. Individuals who are not yet adults (infants, children, teenagers) 23. Individuals who are currently incarcerated or serving a prison sentence 24. Individuals unable to provide informed consent due to factors such as mental incapacity or language barriers 25. Any disorder, inability, or unwillingness to comply with the study protocol that may jeopardize patient safety or compliance, based on the investigator's opinion Pregnancy and Other Exclusions during Trial: 1. If a patient experiences a pregnancy, her data will be censored from the time of estimated conception, and she will be excluded from further participation. 2. If a patient develops active cancer (except skin cancer), they will be excluded from further participation due to safety concerns/contraindications for weight loss. 3. If a patient develops another exclusionary condition, such as unstable angina or another condition for which weight loss or exercise might be contraindicated, further participation will be determined by the Medical Monitoring Team (PI, Project Manager). |
Country | Name | City | State |
---|---|---|---|
United States | Knownwell | Needham | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis | Knownwell |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in weight in kilograms | Effect of GLP1 medications on weight (in kg) | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | |
Other | Changes in waist circumference (cm) | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | ||
Other | Changes in resting metabolic rate (RMR) | Effect of GLP1 medications on resting metabolic rate, assessed by indirect calorimetry. | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | |
Other | Change in weight loss percentage | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | ||
Other | Changes in body fat percentage | Measured by seca mBCA 554 bioelectrical impedance analysis | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | |
Other | Changes in skeletal muscle mass (lbs) | Measured by seca mBCA 554 bioelectrical impedance analysis | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | |
Other | Changes in visceral fat mass (L) | Measured by seca mBCA 554 bioelectrical impedance analysis | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | |
Other | Changes in segmental skeletal muscle mass (lbs) | Measured by seca mBCA 554 bioelectrical impedance analysis | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | |
Primary | Change in Food Craving Score | Effect of GLP1 medications on food cravings measured by the food-craving inventory (FCI-II) questionnaire.The FCI-II is scored on a Likert scale from 1-5, with 1 being "Never," 5 being "Always/Almost every day." | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) | |
Secondary | Change in USDA Healthy Eating Index-2015 (HEI) Score | Effect of GLP1 medications on Healthy Eating Index-2015. The scores range from 0 to 100. An ideal overall HEI score of 100 reflects that the set of foods aligns with key dietary recommendations and dietary patterns published in the Dietary Guidelines. | Baseline, Midpoint (8-12 weeks), End of study (24 + 2 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |